F-Star Alpha Limited

F-star is a clinical-stage company that develops novel bispecific antibodies directed at improving the treatment of serious diseases, with a focus on immuno-oncology and inflammatory diseases. F-star’s Modular Antibody Technology offers unprecedented speed and efficiency in the development and manufacturing of genuine bispecific antibody products.

Headquarters Cambridge, UK
Website www.f-star.com​​
Pipeline Her2 in Phase 1 with Bristol-Myers Squibb; multiple preclinical Immuno-oncology programs
Partners Boehringer Ingelheim, Bristol-Myers Squibb, Merck Serono